|4Jan 4, 8:30 AM ET

Lee Ann 4

4 · Coya Therapeutics, Inc. · Filed Jan 4, 2023

Insider Transaction Report

Form 4
Period: 2022-01-03
Lee Ann
Director
Transactions
  • Conversion

    Common Stock, par value $0.0001 per share

    2023-01-03$4.00/sh+6,479$25,91616,479 total
  • Purchase

    Common Stock, par value $0.0001 per share

    2023-01-03+10,00010,000 total
  • Purchase

    Warrant to Purchase Common Stock

    2023-01-03+5,0009,479 total
    Exercise: $7.50From: 2023-01-03Exp: 2025-01-03Common Stock, par value $0.0001 per share (5,000 underlying)
  • Conversion

    6% Convertible Note

    2023-01-036,479 total
    Exercise: $4.00Common Stock, par value $0.0001 per share (6,479 underlying)
Footnotes (2)
  • [F1]Reporting Person purchased 10,000 shares of Common Stock and accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering ("IPO") at a combined purchase price $5.00 per share and accompanying warrant.
  • [F2]Upon the closing of the Issuer's IPO, the Convertible Note automatically converted into shares of common stock by dividing the then-outstanding principal and interest due under the Convertible Note by $4.00, or 80% of the IPO price. The Reporting Person held a Convertible Note for $25,000 that accrued interest at 6% per annum.

Documents

1 file
  • 4
    ownership.xmlPrimary